display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HER2-positive
es-BC - HER2 positive - (neo)adjuvant (NA)la/mBC - HER2 positive - 2nd Line (L2)
trastuzumab emtansine KATHERINE Harbeck ... EMILIA

Study type: